Update on the evaluation of a new drug for effects on cardiac repolarization in humans: Issues in early drug development

British Journal of Pharmacology

Volumn 159, Issue 1, 2010, Pages 34-48

  Salvi, Vaibhav ^a   Karnad, Dilip R ^a   Panicker, Gopi Krishna ^a   Kothari, Snehal ^a  

^a IQVIA   (United States)

Author keywords

12 lead electrocardiograph; Cardiac safety; Drug induced QT prolongation; Holter monitoring; Study design; Thorough QT QTc study

Indexed keywords

BIOLOGICAL MARKER; CISAPRIDE; MOXIFLOXACIN; TADALAFIL; TERFENADINE;

DEATH; DRUG DETERMINATION; DRUG EFFECT; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYSTERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; SAMPLE SIZE; SENSITIVITY ANALYSIS; TORSADE DES POINTES;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUGS, INVESTIGATIONAL; ELECTROCARDIOGRAPHY; GUIDELINES AS TOPIC; HUMANS; INTERNATIONAL COOPERATION; LONG QT SYNDROME; TORSADES DE POINTES;

EID: 74549216361     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00427.x     Document Type: Review

References (120)

1. Ahmad K, Dorian P (2007). Drug-induced QT prolongation and proarrhythmia: an inevitable link? Europace 9 : iv16 iv22
2. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 : S1 S209.
3. Antzelevitch C (2005). Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2 : S9 S15.
4. Antzelevitch C (2007). Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace 9 : iv4 iv15
5. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM et al. (2004). Electrophysiologic effects of ranolazine: A novel antianginal agent with antiarrhythmic properties. Circulation 110 : 904 910. (Pubitemid 39136212)
6. Anyukhovsky EP, Sosunov EA, Rosen MR (1996). Regional differences in electrophysiological properties of epicardium, midmyocardium, and endocardium. In vitro and in vivo correlations. Circulation 94 : 1981 1988.
7. Ayalasomayajula S, Yeh CM, Vaidyanathan S, Flannery B, Dieterich HA, Howard D et al. (2008). Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects. J Clin Pharmacol 48 : 799 811. (Pubitemid 351871965)
8. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J (2004). Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 44 : 689 695.
9. Batchvarov V, Ghuran A, Smetana P, Hnatkova K, Harries M, Dilaveris P et al. (2002). QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 282 : H2356 H2363.
10. Bazett HC (1920). An analysis of time relations of electrocardiograms. Heart 7 : 353 367.
11. Beasley CM, Mitchell MI, Dmitrienko AA, Emmick JT, Shen W, Costigan TM et al. (2005). The combined use of ibutilide as an active control with intensive ECG sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J Am Coll Cardiol 46 : 678 687.
12. Ben-David J, Zipes DP (1993). Torsades de pointes and proarrhythmia. Lancet 341 : 1578 1582.
13. Bloomfield D, Krishna R (2008). Commentary on the clinical relevance of concentration/QTc relationships for new drug candidates. J Clin Pharmacol 48 : 6 8.
14. Bonate PL, Russell T (1999). Assessment of QTc prolongation for non cardiac related drugs from drug development perspective. J Clin Pharmac 39 : 349 358.
15. Borer J, Armstrong P (2003). Proceedings of the 99th Meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee: May 29th and 30th, 2003. Circulation 17 107 : e9052
16. Committee for Proprietary Medicinal Products (1997). Points to consider: the assessment of the potential for QT interval prolongation by noncardiovascular medicinal products. Available at: http://www.fda.gov/OHRMS/ DOCKETS/ac/03/briefing/pubs%5Ccpmp.pdf
17. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K et al. (2004). Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10 : 96 100.
18. Damle B, Fosser C, Ito K, Tran A, Clax P, Uderman H (2009). Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. J Clin Pharmacol 49 : 291 300.
19. Darpö B (2001). Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl 3 : K70 K80.
20. Davis JD, Hackman F, Layton G, Higgins T, Sudworth D, Weissgerber G (2008). Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Br J Clin Pharmacol 65 : 68 75.
21. Démolis JL, Kubitza D, Tennezé L, Funck-Brentano C (2000). Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 68 : 658 666.
22. Deshmukh S, Karnad DR, Natekar M, Panicker GK, Kothari S, Narula D et al. (2008). Influence of T wave morphology and amplitude on variability in QT interval. Indian Heart J 60 : 448 449.
23. Dessertenne F (1966). La tachycardie ventriculaire à deux foyers opposés variable. Arch Mal Coeur Vaiss 59 : 263.
24. Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K et al. (2008). Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol 66 : 396 404.
25. Dmitrienko A, Beasley C, Mitchell M (2008). Design and Analysis of Thorough QT Studies. Biopharmaceutical Network Report 04:29
26. Eckhardt LL, Rajamani S, January CT (2005). Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome. Br J Pharmacol 145 : 3 4.
27. FDA cardiovascular and renal drugs advisory committee review of ranolazine 2003). Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 4012b2.htm
28. FDA review for Uroxatral (alfuzosin HCL tablets) 2003). Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3956B1.htm
29. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG et al. (2004). Drug-induced torsade de pointes and implications for drug development. J Cardiovasc Electrophysiol 15 : 475 495.
30. Fridericia LS (1920). Duration of systole in electrocardiogram. Acta Med Scandinav 53 : 469.
31. Fung MC, Hsiao-hui Wu H, Kwong K, Hornbuckle K, Muniz E (2000). Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades - 1969-1998. Pharmacoepidemiol Drug Saf 9 : S24
32. Garnett CE, Beasley N, Bhattaram VA (2008). Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 48 : 13 18.
33. Garson A (1993). How to measure the QT interval: what is normal? Am J Cardiol 72 : 14B 16B.
34. Graff C, Andersen MP, Xue JQ, Hardahl TB, Kanters JK, Toft E et al. (2008). T-wave morphology reveals greater effect of D, L-sotalol than QTc. J Electrocardiol 41 : 642 647.
35. Gupta P, Patel C, Patel H, Narayanaswamy S, Malhotra B, Green JT et al. (2008). Tp-e/QT ratio as an index of arrhythmogenesis. J Electrocardiol 41 : 567 574.
36. Harris SC, Hoelscher D, Kristensen A, O'Keefe SA, Schemera A (2005). Effects of buprenorphine transdermal system 10 mg. and 2 x 20 mg on QT intervals in healthy subjects. Clin Pharmacol Ther 79 : P35 P35
37. Health Canada (2006). Question and answer document regarding the ICH S7B and E14 guidances. File number: 06-124711-745 (30 November 2006). Ottawa: Ministry of Health, Health Products and Food Branch. Available at: http://www.hc-sc.gc.ca/dhp-mps/alt-427-formats/hpfb-dgpsa/pdf/prodpharma/ qt-qa-qr-e.pdf (accessed on 9 June 2009).
38. Hingorani P, Karnad DR, Panicker GK, Deshmukh S, Kothari S, Narula D (2008). Differences between QT and RR intervals in digital and digitized paper electrocardiograms: contribution of the printer, scanner, and digitization process. J Electrocardiol 41 : 370 375.
39. Hnatkova K, Malik M (1999 Optimum' formulae for heart rate correction of the QT interval. Pacing Clin Electrophysiol 22 : 1683 1687.
40. Hollister AS, Montague TH (2005). Statistical analysis plans for ECG Data: controlling the intrinsic and extrinsic variability in QT data. In : Morganroth J, Gussak I (eds). Cardiac Safety of NonCardiac Drugs. Humana Press : Humana Press, Totowa, NJ, pp. 239 257.
41. Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A, Stockis A (2007). Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol 63 : 1011 1017.
42. Hulhoven R, Rosillon D, Bridson WE, Meeus MA, Salas E, Stockis A (2008). Effect of levetiracetam on cardiac repolarization in healthy subjects: A single-dose, randomized, placebo- and active-controlled, four-way crossover study. Clin Ther 30 : 260 270.
43. ICH Harmonized Tripartite Guideline E14 (2005). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. Available at: http://www.fda.gov/cder/guidance/6922fnl. htm
44. ICH Harmonized Tripartite Guideline E14 Questions and Answers (2008). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. Available at: http://www.fda.gov/cder/guidance/ 8466fnl.pdf
45. ICH Harmonized Tripartite Guideline S7B (2005). Safety pharmacology assessment of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals. Available at: http://www.fda.gov/cder/ Guidance/6885fnl.htm
46. Iwamoto M, Kost JT, Mistry GC, Wenning LA, Breidinger SA, Marbury TC et al. (2008). Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol 48 : 726 733.
47. Jenzer HR, Hagemeijer F (1976). Quinidine syncope: torsades de pointes with low quinidine plasma concentrations. Eur J Cardiol 4 : 447 451.
48. Julious SA (2004). Sample sizes for clinical trials with normal data. Stat Med 23 : 1921 1986.
49. Kroll CR, Gettes LS (2002). T wave alternans and torsades de pointes after the use of intravenous pentamidine. J Cardiovasc Electrophysiol 13 : 936.
50. Kubitza D, Mueck W, Becka M (2008). Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf 31 : 67 77.
51. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA et al. (2005). Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312 : 316 323.
52. Lau CP, Freedman AR, Fleming S, Malik M, Camm AJ, Ward DE (1988). Hysteresis of ventricular paced QT interval in response to abrupt changes in pacing rate. Cardiovasc Res 22 : 67 72.
53. Lazzerini PE, Acampa M, Guideri F, Capecchi PL, Campanella V, Morozzi G et al. (2004). Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases. Arthritis Rheum 50 : 1248 1252.
54. Lokhandwala Y, Toal SC (2003). The fallacies of QT correction. Indian Pacing Electrophysiol J 3 : 185 186.
55. Lund K, Perkiomaki JS, Brohet C, Elming H, Zaïdi M, Torp-Pedersen C et al. (2002). The prognostic accuracy of different QT interval measures. Ann Noninvasive Electrocardiol 7 : 10 16.
56. Magnano AR, Holleran S, Ramakrishnan R, Reiffel JA, Bloomfield DM (2002). Autonomic nervous system influences on QT interval in normal subjects. J Am Coll Cardiol 39 : 1820 1826.
57. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH (1993). Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270 : 2590 2597.
58. Malhotra BK, Glue P, Sweeney K, Anziano R, Mancuso J, Wicker P (2007). Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 81 : 377 385.
59. Malik M (2001). Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 12 : 411 420.
60. Malik M, Camm AJ (2001). Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 24 : 323 351.
61. Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ (2002). Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 87 : 220 228.
62. Malik M, Andreas JO, Hnatkova K, Hoeckendorff J, Cawello W, Middle M et al. (2008a). Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin Pharmacol Ther 84 : 595 603.
63. Malik M, Hnatkova K, Novotny T, Schmidt G (2008b). Subject-specific profiles of QT/RR hysteresis. Am J Physiol Heart Circ Physiol 295 : H2356 63.
64. Mason J (2009). Does over-encapsulation alter pharmacokinetics or pharmacodynamics of moxifloxacin? Abstract] Presented at DIA conference on QT and arrhythmia issues in drug development. April 29-May 1. Bethesda, MD, USA
65. Modi NB, Nath R, Staehr P, Gupta SK, Aquilina JW, Rivas D (2009). Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects. J Clin Pharmacol 49 : 634 642.
66. Mok NS, Lo YK, Tsui PT, Lam CW (2005). Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug. J Cardiovasc Electrophysiol 16 : 1375 1377.
67. Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE (1996). Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 27 : 76 83.
68. Morganroth J (2007). Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 81 : 108 113.
69. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA (1991). Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 67 : 774 776.
70. Morganroth J, Ilson BE, Shaddinger BC, Dabiri GA, Patel BR, Boyle DA et al. (2004). Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 93 : 1378 1383.
71. Moss AJ, Zareba W, Benhorin J, Couderc JP, Kennedy H, Locati-Heilbron E et al. (2001). ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: task force summary. Ann Noninvasive Electrocardiol 6 : 333 341.
72. Nagy D, DeMeersman R, Gallagher D, Pietrobelli A, Zion AS, Daly D et al. (1997). QTc interval (cardiac repolarization): lengthening after meals. Obes Res 5 : 531 537.
73. Patterson S, Agin M, Anziano R, Burgess T, Chuang-Stein C, Dmitrienko A et al. (2005). Investigating drug-induced QT and QTc prolongation in the clinic: a review of statistical design and analysis considerations. Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team. Drug Inf J 39 : 243 266.
74. Peeters M, Janssen K, Kakuda TN, Schöller-Gyüre M, Lachaert R, Hoetelmans RM et al. (2008). Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. Ann Pharmacother 42 : 757 765.
75. Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR et al. (2006). Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 12 : 3762 3773.
76. Pollard CE, Valentin JP, Hammond TG (2008). Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br J Pharmacol 154 : 1538 1543.
77. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S et al. (1996). Dose-response relation between terfenadine (Seldane) and the QTc interval on the scaler electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 131 : 472 480.
78. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M et al. (2003). Risk stratification in the long-QT syndrome. N Engl J Med 348 : 1866 1874.
79. Ritsema van Eck HJ, Kors JA, van Herpen G (2005). The U wave in the electrocardiogram: a solution for a 100-year-old riddle. Cardiovasc Res 67 : 256 262.
80. Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S et al. (2009). Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 157 : 827 836.
81. Roden DM (2004). Drug-induced prolongation of the QT interval. N Engl J Med 350 : 1013 1022.
82. Roden DM (2008a). Cellular basis of drug-induced torsades de pointes. Br J Pharmacol 154 : 1502 1507.
83. Roden DM (2008b). Keep the QT interval: it is a reliable predictor of ventricular arrhythmias. Heart Rhythm 5 : 1213 1215.
84. Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA et al. (2006). Pharmacogenomics: challenges and opportunities. Ann Intern Med 145 : 749 757.
85. Rosillon D, Astruc B, Hulhoven R, Meeus MA, Troenaru MM, Watanabe S et al. (2008). Effect of brivaracetam on cardiac repolarisation - a thorough QT study. Curr Med Res Opin 24 : 2327 2337.
86. Rudy Y (2007). Modelling the molecular basis of cardiac repolarization. Europace 9 : vi17 vi19
87. Sadanaga T, Sadanaga F, Yao H, Fujishima M (2006). An evaluation of ECG leads used to asses QT prolongation. Cardiology 105 : 149 154.
88. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D (1992). An improved method for adjusting the QT interval for heart rate (the Heart Study). Am J Cardiol 70 : 797 801.
89. Sahashi K, Ozaki M, Fuzita T, Otani Y, Narula D, Desai J et al. (2006). Are physiological loads suitable for non-pharmacological control in thorough QT/QTc studies? Abstract] Presented at International pharmacological conference. Beijing China.
90. Sarapa N, Britto MR (2008). Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin Drug Saf 7 : 305 318.
91. Sarapa N, Morganroth J, Couderc JP, Francom SF, Darpo B, Fleishaker JC et al. (2004). Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods. Ann Noninvasive Electrocardiol 9 : 48 57.
92. Sarapa N, Nickens DJ, Raber SR, Reynolds RR, Amantea MA (2008). Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin Pharmacol Ther 83 : 153 159.
93. Sechaud R, Dumortier T, Balez S (2009). Deferasirox does not induce QT/QTc-prolongation in healthy subjects. Int J Clin Pharmacol Ther 47 : 321 327.
94. Seltzer A, Wray HW (1964). Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias. Circulation 30 : 17 26
95. Serra DB, Affrime MB, Bedigian MP, Greig G, Milosavljev S, Skerjanec A et al. (2005). QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 45 : 1038 1047.
96. Shah RR (2002). The significance of QT interval in drug development. Br J Clin Pharmacol 54 : 188 202.
97. Shah RR (2008). If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed? Pharmacol Ther 119 : 215 221.
98. Shimizu M, Ino H, Okeie K, Yamaguchi M, Nagata M, Hayashi K et al. (2002). T-peak to T-end interval may be a better predictor of high-risk patients with hypertrophic cardiomyopathy associated with a cardiac troponin I mutation than QT dispersion. Clin Cardiol 25 : 335 339.
99. Shimizu W, McMahon B, Antzelevitch C (1999). Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome. J Cardiovasc Electrophysiol 10 : 154 164.
100. Stass H, Dalhoff A, Kubitza D, Schuhly U (1998). Pharmacokinetics, safety and tolerability of ascending single dose of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 42 : 2060 2065.
101. Stockbridge N (2008). Cardiac safety evaluation of large molecules: an FDA perspective Abstract] Presented at Cardiac safety in large molecules: new regulatory expectations, new strategies. February 26. Available at: http://event.on24.com/event/99/29/7/rt/1/documents/slidepdf/quintiles- presentation-slides-v2.pdf (accessed on 2 June 2009).
102. Stramba-Badiale M, Priori SG (2005). Gender-specific prescription for cardiovascular diseases? Eur Heart J 26 : 1571 1572.
103. Stramba-Badiale M, Locati EH, Martinelli A, Courville J, Schwartz PJ (1997). Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. Eur Heart J 18 : 1000 1006.
104. Stratmann HG, Kennedy HL (1987). Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J 113 : 1470.
105. Strnadova C (2008). Health Canada updates: what are the key issues and controversies in Canada? Abstract] Presented at DIA conference on QT and arrhythmia issues in drug development. April 7-8. Bethesda, MD, USA.
106. Sutent (2008 Product Monograph] 17300 Trans-Canada Highway Kirkland, Quebec H9J 2M5: Pfizer Canada Inc.
107. Tsong J Zhong Y, Chen WJ (2008). Validation testing in thorough QT/QTc clinical trials. J Biopharm Stat 18 : 529 541.
108. Tyl B, Azzam S, Olbertz J, Wheeler B (2008). Comparison of four baseline methods on moxifloxacin detection in a thorough QT/QTc study Abstract] Presented at DIA conference on QT and arrhythmia issues in drug development. April 7-8. Bethesda, MD, USA.
109. Vaglio M, Couderc JP, McNitt S, Xia X, Moss AJ, Zareba W (2008). A quantitative assessment of T-wave morphology in LQT1, LQT2, and healthy individuals based on Holter recording technology. Heart Rhythm 5 : 11 18.
110. Vargas HM, Bass AS, Breidenbach A, Feldman HS, Gintant GA, Harmer AR et al. (2008). Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 58 : 72 76.
111. Viitasalo M, Karjalainen J (1992). QT intervals at heart rates from 50 to 120 beats per minute during 24-hour electrocardiographic recordings in 100 healthy men. Circulation 86 : 1439 1442.
112. Vik T, Pollard C, Sager P (2008). Early clinical development: evaluation of drug-induced torsades de pointes risk. Pharmacol Ther 119 : 210 214.
113. Wysowski DK, Bacsanyi J (1996). Cisapride and fatal arrhythmia. N Engl J Med 335 : 290 291.
114. Yan GX, Antzelevitch C (1998). Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98 : 1928 1936. (Pubitemid 28509291)
115. Yao X, Anderson DL, Ross SA, Lang DG, Desai BZ, Cooper DC et al. (2008). Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br J Pharmacol 154 : 1446 1456.
116. Yap YG, Camm AJ (2003). Drug induced QT prolongation and torsades de pointes. Heart 89 : 1363 1372.
117. Zareba W (2002). New Era for Digital ECG: FDA requires digital ECG submission for tested drugs. Ann Noninvasive Electrocardiol 7 : 1 3.
118. Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT et al. (2007). QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol 49 : 146 153. (Pubitemid 46579948)
119. Zhang J (2008). Testing for positive control activity in a thorough QTc study. J Biopharm Stat 18 : 517 528.
120. Zitron E, Scholz E, Owen RW, Lück S, Kiesecker C, Thomas D et al. (2005). QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids. Circulation 111 : 835 838.